Sargent Bickham Lagudis LLC Nautilus Biotechnology, Inc. Transaction History
Sargent Bickham Lagudis LLC
- $1.22 Billion
- Q4 2022
A detailed history of Sargent Bickham Lagudis LLC transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, Sargent Bickham Lagudis LLC holds 425 shares of NAUT stock, worth $1,105. This represents 0.0% of its overall portfolio holdings.
Number of Shares
425
Previous 425
-0.0%
Holding current value
$1,105
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NAUT
# of Institutions
82Shares Held
63.9MCall Options Held
2.9KPut Options Held
500-
Ah Equity Partners Bio Ii, L.L.C. Menlo Park, CA16.3MShares$42.4 Million24.08% of portfolio
-
Perceptive Advisors LLC New York, NY12.6MShares$32.7 Million0.85% of portfolio
-
Cercano Management LLC Bellevue, WA7.17MShares$18.6 Million0.45% of portfolio
-
Madrona Venture Group, LLC6.02MShares$15.7 Million15.03% of portfolio
-
Black Rock Inc. New York, NY3.83MShares$9.95 Million0.0% of portfolio
About Nautilus Biotechnology, Inc.
- Ticker NAUT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,663,000
- Market Cap $324M
- Description
- Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...